Search
D-threo-neopterin
go.drugbank.com/drugs/DB02385Experimental(From Stedman, 26th ed) Neopterin also serves as a precursor in the biosynthesis of biopterin. … A pteridine derivative present in body fluids; elevated levels result from immune system activation, malignant disease, allograft rejection, and viral infections.
N-chlorotaurine
go.drugbank.com/drugs/DB06633ExperimentalN-chlorotaurine is an inhibitor of inducible nitric oxide synthase and IkappaB kinase.
Synonyms: N-chlorotaurine, N-monochlorotaurineBifunctional epoxide hydrolase 2
go.drugbank.com/drugs/DB15139InvestigationalBifunctional epoxide hydrolase 2 is under investigation in clinical trial NCT00654966 (Evaluation of the Effects of Urotensin-II and Soluble Epoxide Hydrolase Inhibitors on Skin Microvessel Tone in Patients … With Heart Failure, and in Healthy Volunteers).
Thenalidine
go.drugbank.com/drugs/DB04826ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1963 due to concerns involving neutropenia.
Synonyms: 1-Methyl-4-amino-N-phenyl-N-(2-thenyl)piperidine, 1-Methyl-4-N-2-thenylanilinopiperidineAllogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells
go.drugbank.com/drugs/DB15740InvestigationalIn humans, OM-MSCs are derived from the olfactory mucosa which is collected in vivo through rhinoscopy techniques and nasal forceps. … Human olfactory mucosa-derived mesenchymal stem cells (OM-MSCs) reside in an accessible location of the nasal cavity and have properties of multipotency and high proliferation, which contributes to high
Bopindolol
go.drugbank.com/drugs/DB08807ExperimentalBopindolol (INN) is an ester prodrug for the beta blocker [pindolol].
Milataxel
go.drugbank.com/drugs/DB12334InvestigationalMilataxel has been used in trials studying the treatment of Mesothelioma.
STC3141
go.drugbank.com/drugs/DB16475InvestigationalSTC3141, was investigated in clinical trial NCT04880694 to evaluate its safety and effect in subjects with severe COVID-19 pneumonia.
Bosakitug
go.drugbank.com/drugs/DB19101InvestigationalBosakitug (BSI-045B) is under investigation in clinical trial NCT05932654 (POC Study to Evaluate BSI-045B Monotherapy and BSI-045B Add-on Therapy With Dupilumab in Atopic Dermatitis).
Banoxantrone
go.drugbank.com/drugs/DB04975InvestigationalBanoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. … Banoxantrone was also efficacious in tumour models when administered in combination with either cisplatin or chemoradiation. [A3115]